FDA introduced three new rare disease pathways over 16 months: the plausible mechanism pathway in November 2025, the Rare Disease Evidence Principles (RDEP) in September 2025, and the Commissioner’s National Priority Voucher in June 2025. They join eight existing mechanisms, from Fast Track to Orphan Drug designation, that the agency has been building since 1983.
The plausible mechanism pathway is narrow: it covers individualized therapies targeting a specific pathophysiologic abnormality, with genome editing and RNA-based treatments as the focus. FDA draft guidance in February 2026 clarified the framework but provided little new information, according to former FDA oncology division director Harpreet Singh. PhRMA called for examples and clarifications in multiple areas in its response to the agency. RDEP targets diseases affecting fewer than 1,000 U.S. patients, driven by a known genetic defect, where there is significant unmet medical need.
Eva Temkin of Arnold & Porter, who advises biopharma on drug development and approval, said sponsors should use new and old pathways concurrently. Arnold & Porter’s analysis flags open questions around regulatory exclusivities and competitive impact for drugs cleared under the plausible mechanism framework, plus unresolved postmarketing obligations.
The structural question is whether faster review translates to better commercial terms. If drugs cleared via the plausible mechanism pathway don’t carry the same exclusivity protections as traditional accelerated approval, sponsors face a faster route to market with weaker protection. That’s not obviously an improvement. The rare pediatric disease PRV program was reauthorized in February 2026 and sunsets September 30, 2029, but its interaction with the new pathways isn’t settled.
Comment period on the plausible mechanism draft guidance closes April 27, 2026.
Sarah Chen